Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib/II Trial of Epcoritamab Plus Ibrutinib in Patients With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

NCT06536049 is registered in ClinicalTrials.gov with Yazeed Sawalha as lead sponsor.

NCT NCT06536049
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06536049 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib/II Trial of Epcoritamab Plus Ibrutinib in Patients With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
Lead sponsor
Yazeed Sawalha
Phase
Phase 1/2
Overall status
Recruiting
Start date
April 2, 2025
Completion date
October 31, 2027
Enrollment
38 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent diffuse large b-cell lymphoma, recurrent grade 3b follicular lymphoma, recurrent high grade b-cell lymphoma with myc and bcl2 or bcl6 rearrangements, recurrent high grade b-cell lymphoma with myc, bcl2, and bcl6 rearrangements, recurrent high grade b-cell lymphoma, not otherwise specified, recurrent primary mediastinal large b-cell lymphoma, recurrent transformed non-hodgkin lymphoma, refractory diffuse large b-cell lymphoma, refractory grade 3b follicular lymphoma, refractory high grade b-cell lymphoma with myc and bcl2 or bcl6 rearrangements, refractory high grade b-cell lymphoma with myc, bcl2, and bcl6 rearrangements, refractory high grade b-cell lymphoma, not otherwise specified, refractory primary mediastinal large b-cell lymphoma, refractory transformed non-hodgkin lymphoma